Indivior Announces H1 and Q2 2022 Financial Results
Indivior PLC (LON: INDV) reported its financial results for the period ending June 30, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Indivior PLC (LON: INDV) reported its financial results for the period ending June 30, 2022. The company continues to focus on developing treatments for substance use disorders, with a pipeline that aims to address related chronic conditions. Earnings and investor presentation details are available on their website. The live webcast presentation hosted by CEO Mark Crossley is scheduled for July 28 at 1:00 PM BST. Indivior employs over 900 individuals globally and offers products in over 40 countries.
Positive
- Continued commitment to developing medicines for substance use disorders.
- Global portfolio of opioid use disorder treatments available in over 40 countries.
Negative
- None.
Details
News Market Reaction – INVVY
The recorded move for INVVY in the trading session of this news was +7.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SLOUGH, U.K. and RICHMOND, Va., July 28, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending June 30, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com.
- The earnings release can be found at www.indivior.com/en/media/press-releases
- The investor presentation can be found at www.indivior.com/investors by 7:00 a.m. EDT July 28, 2022
There will be a live webcast presentation at 13:00 BST (8:00 a.m. EDT) hosted by Mark Crossley, CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/n3frngii
Participants may access the presentation telephonically by registering here.
(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-h1-and-q2-2022-financial-results-301594927.html
SOURCE Indivior
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.